Santa Barbara, CA, United States of America

David H Crean

This inventor holds 2 USPTO granted patents. Top assignees: University of California, Other. Active years: 2000-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David H Crean. Retrieved from https://idiyas.com/inventor/david-h-crean

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2000-2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: David H Crean: Innovator in Photodynamic Therapy

Introduction

David H Crean is a notable inventor based in Santa Barbara, CA (US). He has made significant contributions to the field of photodynamic therapy, particularly in the treatment of ocular viral diseases. With a total of 2 patents, his work focuses on innovative methods that enhance the efficacy and safety of medical treatments.

Latest Patents

David H Crean's latest patents include groundbreaking methods for treating ocular viral pathogens. One of his patents, titled "Phototherapeutic inactivation of ocular viruses," describes a method for inactivating ocular viral pathogens and treating associated lesions on tissue. This method involves the use of a tissue-associated photosensitizing agent, preferably tin ethyl etiopurpurin, which is administered to a patient to concentrate within the lesionous target tissue of the eye. The photosensitizer-laden target tissue is then irradiated with photoactivating light, effectively inactivating both cell-free Herpes simplex virus (HSV) and cell-associated HSV and cytomegalovirus (CMV). This approach reduces toxicity to the biological system compared to prior therapeutic procedures.

Another patent, "Method for photo-altering a biological system to improve biological," presents photodynamic therapy as an adjunctive therapy for filtration surgery. This method does not rely on chemotherapy agents or radiation but instead uses pharmacologically-active sensitizing compounds to achieve a localized, transient, post-operative avascular conjunctiva. The photosensitizing agent is selectively activated, allowing for a predetermined biological effect, thus improving the spatial disposition and effectuation of the biological effect within the biological system.

Career Highlights

Throughout his career, David H Crean has worked with prestigious institutions, including the University of California. His innovative research has paved the way for advancements in medical treatments, particularly in the realm of ocular health.

Collaborations

David has collaborated with notable individuals in his field, including Richard A Hill and Daniel R Doiron. Their combined expertise has contributed to the development of effective therapeutic methods.

Conclusion

David H Crean stands out as an influential inventor in the field of photodynamic therapy, with a focus on ocular health. His innovative patents reflect a commitment to improving medical treatments and patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…